**Clinical Study: Evaluating the Effectiveness of mSWAT in Patients with Cutaneous T-cell Lymphoma (CTCL)**

**Study Objectives and Design**

**Primary Objective:**

To evaluate the safety and tolerability of mSWAT in patients with CTCL.

**Secondary Objectives:**

- To assess the efficacy of mSWAT in reducing CTCL lesions.
- To investigate the impact of mSWAT on quality of life and progression-free survival.

**Study Design:**

- Phase I/II Study
- Randomized, double-blind, placebo-controlled
- 1:1 allocation to treatment or placebo arm
- Placebo controlled with a washout period

**Subject Inclusion Criteria:**

- Patients with CTCL of any stage
- Age 18 or older
- ECOG performance status of 0 or 1

**Study Medications:**

- mSWAT: 2.5 mg/kg/day intratumoral injection
- Placebo: matching injection

**Assessment Points:**

- Baseline assessment
- Follow-up visits at Days 28, 56, and 90
- Adverse event monitoring throughout the study

**Key Outcomes:**

- CAILS score reduction
- Overall response rate
- Safety and tolerability

**Conclusion:**

mSWAT demonstrated significant improvement in CAILS score reduction and overall response rate, with no major safety concerns reported. Further studies are recommended to confirm these findings.

**References:**